Stuart Therapeutics

    Company Information

    Stuart Therapeutics is based in Stuart, Florida, USA. The number of employees in Stuart Therapeutics is unknown. Stuart therapeutics is a biotechnology company that offers polycol, a therapeutic platform for ophthalmic indications.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Stuart Therapeutics has received 1 rounds of venture funding. The total funding amount is around $11M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Stuart Therapeutics - Blog

                          • Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital

                          • Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the completion of an $11 million Series A round of capital investment. The round was led by InFocus Capital Partners, an ophthalmology-focused life sciences venture capital fund, with significant participation by the Wisconsin
                          • Stuart Therapeutics Wins the AdvanSE Life Sciences Conference PitchRounds Competition

                          • November 13th, 2020, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that the company’s presentation at the Southeast Life Sciences AdvanSE Life Sciences Conference was judged the winner of the PitchRounds Competition.  The competition drew applications from over 70 applications.  Twenty companies were selected
                          • Stuart Therapeutics, Inc. Announces Presentation at ARVO 2020

                          • Stuart Therapeutics, Inc. (STUART), the leader in the application of collagen mimetic peptide (CMP) technology for ophthalmology, today announced that it has been selected as a presenter at the Association for Research of Vision and Ophthalmology (ARVO) 2020 Annual Meeting in Baltimore, Maryland, May 3rd through 7th at the Baltimore Convention Center. The presentation is
                          • Stuart Therapeutics, Inc. Announces Pro-Neuronal Growth Results Using PolyColTM Collagen Mimetic Peptides

                          • STUART, FLORIDA November 11th, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical therapeutic development company, today announced that it has successfully completed in vitro pro-neuronal growth experiments utilizing the company’s PolyColTM (PolyCol) peptide. PolyCol demonstrated a strong propensity to encourage neurite outgrowth from dorsal root ganglia nerve cells in a model designed to mirror damage
                          • Stuart Therapeutics, Inc. Announces a Strategic Partnership with Ora, Inc.

                          • STUART, FLORIDA June 12, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical ophthalmic therapeutic development company, today announces it has entered into a strategic partnership with Ora®, Inc. (“ORA”), the premier global ophthalmology contract research organization.  ORA is investing in its partnership with STUART by providing CMC program execution, IND preparation, and related strategic consulting
                          • Stuart Therapeutics Announces Positive Retinal Indication in vitro Results for PolyCol

                          • April 22nd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc., a pre-clinical stage life sciences company developing solutions for difficult to treat ophthalmic diseases, today announced positive results from in vitro experiments using its proprietary collagen mimetic peptide (CMP), PolyColTM (PolyCol) to probe applicability for conditions associated with dry age-related macular degeneration (Dry AMD). 

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *